Prevalence, diagnostic challenges, and management strategies for attention deficit hyperactivity disorder in children

Nº de DOI: 10.34896/RSI.2025.71.76.001

 AUTHORS

1. Michael Gustavo Miranda Coello. General Practitioner. Attached to Clínica los Pinos. Graduate of the Higher Polytechnic School of Chimborazo. (Quito-Ecuador). https://orcid.org/0000-0003-1896-9234
2. Johanna Vanesa Goya Trujillo. General Practitioner. Attached to Klinic. Graduate of the University of Guayaquil. (Guayaquil-Ecuador). https://orcid.org/0009-0002-4828-9926
3. Joselyn Beatriz Paredes Flores. General Practitioner. Attached to the MEDIVALLE Medical Specialties Center. Graduate of the Regional Autonomous University of the Andes. (Pelileo-Ecuador). https://orcid.org/0009-0002-6046-5945
4. Lilia Patricia Coles ChelaGeneral Practitioner. Attached to the José María Velasco Ibarra Hospital. Graduate of the Technical University of Ambato. (Carlos Julio Arosemena Tola-Ecuador). https://orcid.org/0009-0005-3612-5010
5. Marcela Sofia Guerrero Cabrera. General Practitioner. Attached to CETAD 12 Steps. Graduate of the Catholic University of Cuenca. (Cuenca-Ecuador). https://orcid.org/0009-0002-5949-3762

SUMMARY

Attention Deficit Hyperactivity Disorder (ADHD) is one of the most prevalent neurodevelopmental disorders affecting children worldwide, characterized by persistent patterns of inattentiveness, hyperactivity, and impulsivity that can significantly impair academic performance, social interactions, and overall quality of life. The epidemiological landscape of ADHD reveals considerable variability, with current statistics indicating that the disorder affects approximately 5-10% of children globally, though prevalence rates fluctuate across different regions and populations due to factors such as differing diagnostic criteria, cultural perceptions, and healthcare accessibility. This variability underscores the complex challenge of accurately estimating the true burden of ADHD and highlights the importance of understanding the underlying factors contributing to these disparities.

KEY WORDS

Attention deficit hyperactivity disorder, pediatric neurodevelopment, epidemiology, diagnostic challenges, behavioral interventions, pharmacological treatment.

RESUMEN

El Trastorno por Déficit de Atención e Hiperactividad (TDAH) es uno de los trastornos del neurodesarrollo más prevalentes que afectan a los niños en todo el mundo. Se caracteriza por patrones persistentes de inatención, hiperactividad e impulsividad que pueden afectar de manera significativa el rendimiento académico, las interacciones sociales y la calidad de vida en general. El panorama epidemiológico del TDAH muestra una variabilidad considerable; las estadísticas actuales indican que el trastorno afecta aproximadamente al 5–10 % de la población infantil a nivel global, aunque las tasas de prevalencia fluctúa entre distintas regiones y poblaciones debido a factores como diferencias en los criterios diagnósticos, percepciones culturales y el acceso a los servicios de salud. Esta variabilidad pone de manifiesto la complejidad de estimar con precisión la verdadera carga del TDAH y resalta la importancia de comprender los factores subyacentes que contribuyen a estas disparidades.

PALABRAS CLAVE

Trastorno por déficit de atención e hiperactividad, neurodesarrollo pediátrico, epidemiología, desafíos diagnósticos, intervenciones conductuales, tratamiento farmacológico.

INTRODUCTION

Diagnosing ADHD in pediatric populations presents its own set of challenges, as clinicians must navigate obstacles like overlapping symptoms with other neurodevelopmental or emotional disorders, the presence of comorbid conditions such as anxiety or learning disabilities, and limitations inherent in existing diagnostic tools and criteria, which may lead to underdiagnosis or misdiagnosis. Effective management of ADHD in children requires a multifaceted approach that combines pharmacological treatments—such as stimulant and non-stimulant medications—with behavioral and psychosocial interventions aimed at improving functional outcomes. However, long-term management remains a significant hurdle, with issues related to medication adherence, side effects, and the need for sustained behavioral support posing ongoing challenges for clinicians, patients, and families alike. Given the considerable impact of ADHD on affected children and their families, it is imperative to deepen our understanding of its prevalence, refine diagnostic strategies, and develop comprehensive management protocols that address the diverse needs of this vulnerable population, making this an essential focus of ongoing research and clinical practice.

OBJECTIVE

Deepening our understanding of its prevalence, refining diagnostic strategies, and developing comprehensive treatment protocols that address the diverse needs of this vulnerable population make it an essential focus of ongoing research and clinical practice.

METHODOLOGY

This narrative review was conducted through a comprehensive analysis of peer-reviewed literature, epidemiological reports, and clinical guidelines related to the prevalence, diagnosis, and management of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric populations. Sources were identified using electronic databases including PubMed, Scopus, Web of Science, and Google Scholar, focusing on studies published within the last fifteen years to ensure inclusion of contemporary diagnostic frameworks and therapeutic practices. Search terms included combinations of “ADHD prevalence,” “pediatric ADHD diagnosis,” “ADHD treatment adherence,” “behavioral interventions,” and “pharmacological management.” Studies were selected based on methodological rigor, relevance to childhood ADHD, and applicability to clinical practice. Data extracted from selected studies were synthesized qualitatively, emphasizing epidemiological patterns, regional and demographic disparities, diagnostic limitations, and evidence-based management strategies. Special attention was given to research addressing long-term treatment challenges, adherence issues, and the integration of behavioral and pharmacological modalities. This methodological approach allowed for a comprehensive evaluation of current knowledge, identification of gaps, and formulation of insights to inform future research and clinical practice.

RESULTS

Prevalence of Attention Deficit Hyperactivity Disorder in Children:

What are the current epidemiological statistics for ADHD in children?

Recent epidemiological statistics underscore the significant impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on the pediatric population, revealing it as one of the most common neurodevelopmental disorders in childhood¹. Globally, the prevalence of ADHD among children is estimated to be about 5 percent, though pooled prevalence estimates and confidence intervals suggest a range closer to 7.2% (with a 95% confidence interval between 6.7% and 7.8%), reflecting variations in diagnostic criteria, study populations, and regional reporting practices¹. In the United States specifically, the prevalence appears higher, with estimates indicating that 11.4% of children equivalent to over 7 million children aged 3-17 years had received a diagnosis of ADHD as of 2022². These patterns are not uniform across age groups, diagnosis rates increase with age, as shown by the markedly lower prevalence among children aged 3-5 years (2.4%) compared to those aged 6-11 years (11.5%), and further rising among adolescents². This age stratification is closely linked to developmental, behavioral, and educational domains, as older children and adolescents are both more likely to be diagnosed and to receive medication, highlighting the interconnectedness of health care, education, and social support systems³. Furthermore, the substantial regional and demographic differences in prevalence such as higher rates among males and notable state-level variations underscore the importance of context-aware surveillance, policy interventions, and resource allocation³. As ADHD diagnoses continue to rise, particularly in the aftermath of the COVID-19 pandemic, there is a pressing need for coordinated efforts across clinical, educational, and public health spheres to ensure accurate identification, equitable access to care, and holistic support for affected children and their families³.

How do prevalence rates of ADHD vary across different regions or populations?

Regional and racial disparities in ADHD prevalence highlight the complexity of factors influencing diagnosis rates across populations. In the United States, the Midwest (10.43%) and South (9.76%) consistently report higher ADHD prevalence compared to the West (8.01%) and Northeast (8.04%), suggesting that local environmental factors, healthcare accessibility, and socioeconomic conditions may play a significant role in shaping these regional differences⁴. This pattern is further complicated by distinct prevalence rates among racial groups, with Black individuals exhibiting the highest reported rates at 9.71% and Asian individuals the lowest at 5.05%, indicating the need for culturally sensitive approaches to ADHD diagnosis and treatment⁴. These variations are not solely attributable to the underlying symptom load within populations, as research suggests that other determinants such as access to diagnostic facilities, diagnostic culture, and community socioeconomic status interact to influence observed rates^5,6. Therefore, understanding the interconnections between geographic, demographic, and sociocultural factors is crucial for developing targeted interventions, improving resource allocation, and ensuring equitable ADHD management across diverse regions and populations⁴. This underscores the importance of tailoring regional strategies and healthcare policies to address the unique needs and challenges faced by specific communities.

What factors contribute to variability in reported prevalence rates?

Beyond regional and environmental influences, methodological and contextual factors play a critical role in the variability of reported prevalence rates across epidemiological studies. The choice of study setting for instance, whether research is conducted in prisons, hospitals, or among the general community can dramatically shape prevalence estimates, as certain environments may concentrate or disperse cases due to unique population characteristics or access to healthcare services⁷. Geographic region is intricately connected to these differences, as local healthcare infrastructure, population demographics, and cultural attitudes toward diagnosis and reporting can all influence data, compounding the challenge of drawing direct comparisons across studies⁷. Furthermore, methodological differences such as study design (cross-sectional versus cohort), sample size, and the diagnostic criteria employed can lead to notable discrepancies in prevalence rates, with smaller, less representative samples or evolving diagnostic standards potentially producing outlier or non-comparable findings⁷.

Diagnostic Challenges of ADHD in Pediatric Populations:

What are the primary obstacles in accurately diagnosing ADHD in children?

One of the primary obstacles in accurately diagnosing ADHD in children stems from the significant overlap between ADHD symptoms and behaviors that are frequently observed in typically developing children, which adds a layer of ambiguity to the diagnostic process⁸. This challenge is compounded by the persistent pattern of inattention and hyperactive behavior characteristic of ADHD, which is not always consistently distinguishable from normal variations in childhood behavior or other psychological conditions^9,10. The variability in symptom severity and expression among children and teenagers further complicates the situation, as some children may display pronounced symptoms while others exhibit subtler manifestations that can be mistaken for typical developmental fluctuations or other disorders¹⁰. Moreover, the transdiagnostic nature of symptoms such as impulsivity, inattention, and restlessness means these indicators can be present across a spectrum of mental health conditions, including mood and anxiety disorders, making it difficult for clinicians to accurately attribute them solely to ADHD¹⁰. This interconnectedness of symptom domains requires mental health professionals to conduct thorough, multi-modal assessments that consider not only symptom presentation but also developmental history and family context, in order to untangle overlapping symptoms and identify any underlying or comorbid conditions¹⁰. Without such comprehensive evaluations and the involvement of skilled practitioners who understand the nuances of typical development and cultural norms, the risk of misdiagnosis remains high, emphasizing the need for a meticulous, collaborative, and context-sensitive approach to ADHD assessment in children¹⁰.

What are the limitations of existing diagnostic criteria and tools for ADHD?

A key limitation of existing diagnostic criteria and tools for ADHD is their inadequate sensitivity to the complexities of adult presentations and the challenges they pose for accurate identification and management across the lifespan. For instance, the DSM-IV criteria, historically applied to both children and adults, fail to account for age-specific symptomatology, as adults often manifest ADHD differently from children, leading to underdiagnosis or misdiagnosis in the adult population¹¹. This issue is compounded by the fact that many adults with ADHD do not recall early symptoms, making retrospective diagnosis difficult and heavily reliant on subjective reports or incomplete childhood documentation¹¹. Furthermore, the expansion of diagnostic criteria to better encompass adult experiences such as lowering the symptom threshold from six to five for adults, and raising the age of onset from 7 to 12 years reflects recognition that earlier tools were too restrictive and not sufficiently inclusive for diverse age groups¹². These changes, while beneficial, also highlight the variability and evolving nature of ADHD diagnostic standards, which can affect consistency and reliability in clinical practice. The interconnection between these limitations is significant: when adult presentations are overlooked due to child-centric criteria, and when subjective recall of early symptoms is unreliable, adults may remain undiagnosed and untreated, potentially leading to greater distress and adverse outcomes. Therefore, ongoing refinement of diagnostic frameworks and increased awareness of adult ADHD presentations are essential to improve detection, ensure equitable access to care, and mitigate the risks associated with missed or delayed diagnosis.

Management Strategies for ADHD in Children:

What are the recommended pharmacological treatments for pediatric ADHD?

The primary pharmacological treatments recommended for pediatric ADHD are stimulant medications, with methylphenidate and amphetamine-based drugs constituting the cornerstone of medical management¹³. Methylphenidate-based medications, such as Ritalin, Metadate, Concerta, Quillivant XR, and Jornay PM, are widely used and often serve as the initial therapeutic option for many children diagnosed with ADHD¹³. Similarly, amphetamine-based medications including Adderall, Vyvanse, Dynavel XR, and Adzenys XR provide comparable efficacy and are frequently considered when methylphenidate is not sufficiently effective or well-tolerated¹³. The choice between these two drug classes is typically individualized, based on factors such as patient response, side effect profile, and dosing convenience, reflecting the interconnectedness of clinical outcomes, family preferences, and quality of daily functioning. Notably, the majority of children prescribed stimulant medications experience significant improvement in ADHD symptoms, which underscores the centrality of pharmacological intervention in achieving better academic, behavioral, and social outcomes¹³. Despite these benefits, it is essential to monitor each child closely and adjust the treatment regimen as needed, often necessitating a trial of different medications or formulations until the optimal balance of efficacy and tolerability is achieved¹³. This dynamic, responsive approach highlights the need for ongoing clinical oversight to maximize benefits while minimizing potential adverse effects, reinforcing the importance of multidisciplinary collaboration and caregiver engagement in pediatric ADHD management.

How effective are behavioral and psychosocial interventions in managing ADHD?

Behavioral and psychosocial interventions are widely recognized as critical and effective components in the comprehensive management of ADHD, addressing both core symptoms and the associated functional impairments across various domains of a child’s life¹⁴. Interventions such as behavioral parent training, classroom management techniques, peer interventions, and organization skills training have demonstrated robust efficacy for children and adolescents with ADHD, not only mitigating symptoms but also equipping these individuals with essential skills that have lifelong utility^14,15. These interventions extend beyond symptom control, targeting academic challenges, interpersonal relationships, and family functioning, thereby fostering holistic improvement. Importantly, the application of behavioral strategies equips parents and teachers with practical tools to support children, creating a collaborative and consistent environment across home and school contexts¹⁴. The interconnectedness of these domains is evident, as academic progress and social competence are closely tied to behavioral regulation, and improvements in one area can catalyze positive changes in others. Despite strong scientific evidence affirming the effectiveness of these interventions, a persistent gap exists between research and real-world implementation, particularly in community and educational settings, underscoring the urgent need for systemic efforts to bridge this divide and ensure equitable access to evidence-based care¹⁵. As such, prioritizing the widespread adoption and integration of behavioral and psychosocial interventions is essential for optimizing outcomes and quality of life for individuals with ADHD.

What challenges exist in long-term management and treatment adherence for children with ADHD?

Long-term management and treatment adherence for children with ADHD are complicated by a constellation of interrelated challenges that span clinical, familial, and systemic domains. One core issue is the difficulty families and patients experience in openly disclosing adherence concerns, which often leads to a discrepancy between reported and actual medication adherence, as observed in clinical trials¹⁶. This underreporting can impede appropriate clinical responses and hinders effective care coordination, especially when information sharing across different points of care is inadequate, further compounding obstacles to sustained management¹⁷. Complicating matters, traditional medical approaches have not sufficiently addressed the ongoing need for continuous monitoring and promotion of adherence, resulting in suboptimal maintenance of treatment gains despite initial improvements from medication or behavioral therapies^16,17. Moreover, patient and parent education alone has proven insufficient, suggesting that interventions must go beyond information dissemination and target deeper systemic and relational factors, such as fostering patient-physician trust and facilitating open, ongoing dialogue about treatment challenges¹⁶. The interplay between these domains underscores the necessity for comprehensive, multi-level interventions that prioritize both structural improvements in healthcare delivery and the cultivation of trustful, collaborative relationships among patients, families, and providers. Without such efforts, the risk persists that children with ADHD will not achieve lasting improvements, and their unmet mental health needs may continue to detrimentally affect their trajectories into adulthood¹⁸. This highlights the urgent need for integrated approaches that can bridge communication gaps, sustain adherence, and ultimately optimize long-term outcomes for this vulnerable population.

DISCUSSION

The findings of this study underscore the substantial global and regional prevalence of ADHD in children, emphasizing its status as a significant public health concern. The notably higher rates in the United States, particularly among older children and adolescents, highlight developmental and educational factors that influence diagnosis, while regional and demographic disparities point to underlying socio-cultural, economic, and healthcare access issues. These disparities underscore the importance of culturally sensitive diagnostic practices and tailored intervention strategies to address the unique needs of diverse populations. The diagnostic challenges identified stemming from symptom overlap with typical behaviors and comorbid conditions highlight the necessity for comprehensive, multi-modal assessment approaches conducted by trained professionals. Limitations of existing diagnostic criteria, such as the DSM standards, especially in accurately capturing adult ADHD, suggest an ongoing need to refine diagnostic tools to improve sensitivity and specificity across age groups. The predominance of pharmacological interventions, particularly stimulant medications, aligns with current evidence of their efficacy but also raises concerns regarding long-term adherence, side effects, and the importance of integrating behavioral and psychosocial interventions. Despite strong support for these approaches, their inconsistent application in community settings reveals systemic gaps in healthcare delivery, which may hinder optimal outcomes. Future research should focus on developing standardized, culturally adaptable diagnostic criteria and promoting integrated treatment models that combine medication with behavioral therapies, ensuring accessibility and sustained engagement. Additionally, longitudinal studies are necessary to better understand the long-term effects of various treatment modalities and to identify best practices for maintaining adherence over time. Recognizing these limitations, it is imperative that clinical, educational, and public health sectors collaborate to implement comprehensive strategies that improve early detection, reduce disparities, and support children and families affected by ADHD. Such efforts will be crucial in advancing understanding, refining management approaches, and ultimately enhancing the quality of life and functional outcomes for children with ADHD across diverse populations.

CONCLUSIONS

1. The findings of this review highlight the substantial global burden of ADHD in pediatric populations, placing it among the most prevalent neurodevelopmental disorders worldwide. Prevalence rates vary significantly across countries, regions, and demographic groups, reflecting differences in diagnostic practices, healthcare access, socio-cultural attitudes, and methodological approaches to epidemiological research. These disparities underscore the need for strengthened surveillance systems and standardized diagnostic frameworks that improve comparability and ensure equitable identification of ADHD across diverse settings.
2. Diagnostic challenges persist due to the considerable overlap between ADHD symptoms and typical childhood behaviors, as well as the frequent co-occurrence of other neurodevelopmental or psychiatric conditions. Limitations in current diagnostic criteria, particularly their historical emphasis on childhood presentations, further complicate accurate identification. These constraints highlight the importance of multi-modal assessment techniques, clinician training, and culturally informed diagnostic practices to improve sensitivity, specificity, and early detection.
3. Management strategies for ADHD continue to rely heavily on pharmacological treatment, particularly stimulant medications, which demonstrate robust efficacy in reducing core symptoms. However, optimal outcomes require the integration of behavioral and psychosocial interventions that address broader functional impairments affecting academic performance, emotional regulation, and social development. Despite strong evidence supporting these approaches, gaps in implementation—especially in community and school settings—limit their real-world impact.
4. Long-term management remains particularly challenging, as adherence to medication and behavioral programs often declines over time due to side effects, stigma, insufficient monitoring, and inconsistent communication between families and healthcare providers. These interrelated challenges emphasize the necessity for coordinated, multidisciplinary care models that provide sustained support and adapt to the evolving needs of children with ADHD and their families.
5. Overall, this review reinforces the need for continued research focused on refining diagnostic tools, developing culturally adaptable assessment frameworks, improving equitable access to evidence-based interventions, and understanding long-term outcomes across developmental stages. Collaborative efforts between clinicians, educators, policymakers, and families will be essential for enhancing early identification, optimizing treatment pathways, and ultimately improving the quality of life and future trajectories of children living with ADHD.

REFERENCES

1. ADHD Science & Strategies. ADHD Statistics: New ADD Facts and Research [Internet]. ADDitude. 2006 [cited 2024 Dec 10]. Available from: https://www.additudemag.com/statistics-of-adhd/?srsltid=AfmBOopaSW9_IWBkm-OGEKR-Lw3pazkI5Nz3A4EWXR3-jR7GU9oehDPV
2. National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder (ADHD) [Internet]. www.nimh.nih.gov. National Institute of Mental Health, 2020 [cited 2024 Dec 10]. Available from: https://www.nimh.nih.gov/health/statistics/attention-deficit-hyperactivity-disorder-adhd
3. Bozinovic K, McLamb F, O’Connell K, Olander N, Feng Z, Haagensen S, et al. U.S. national, regional, and state-specific socioeconomic factors correlate with child and adolescent ADHD diagnoses pre-COVID-19 pandemic. Scientific Reports [Internet]. 2021 Nov 10 [cited 2024 Dec 10],11(1):22008. Available from: https://doi.org/10.1038/s41598-021-01233-2
4. Patil M, Konda S, Ganti L. Assessing ADHD prevalence and comorbidities in the United States: Insights from the Substance Abuse and Mental Health Services (SAMHSA) data. Cambridge Prisms Global Mental Health [Internet]. 2024 Jan 1 [cited 2024 Dec 10],11(1). Available from: https://doi.org/10.1017/gmh.2024.104
5. Madsen KB, Ersbøll AK, Olsen J, Parner E, Obel C. Geographic analysis of the variation in the incidence of ADHD in a country with free access to healthcare: a Danish cohort study. International Journal of Health Geographics [Internet]. 2015 Aug 22 [cited 2024 Dec 10],14(1). Available from: https://doi.org/10.1186/s12942-015-0018-4
6. Hofstad T, Nyttingnes O, Bjelland I, Mykletun A. Catchment area characteristics do not account for geographical variation in ADHD diagnoses. European Child & Adolescent Psychiatry [Internet]. 2025 Apr 24 [cited 2025 Apr 26],34(1). Available from: https://doi.org/10.1007/s00787-025-02720-x
7. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review. BMC Psychiatry [Internet]. 2015 Aug 12 [cited 2024 Dec 10],15(1). Available from: https://doi.org/10.1186/s12888-015-0578-7
8. Miller C. How to get an ADHD diagnosis [Internet]. Child Mind Institute. 2023 [cited 2024 Dec 10]. Available from: https://childmind.org/article/how-to-get-an-adhd-diagnosis/
9. Bilodeau N. 9 ADHD Diagnosis Techniques For Children [Internet]. Skill Point Therapy. 2024 [cited 2024 Dec 10]. Available from: https://www.skillpointtherapy.com/9-adhd-diagnosis-techniques-for-children/
10. 10.Young S, Absoud M, Al-Attar Z, Ani C, Colley W, Cortese S, et al. The ADHD Assessment Quality Assurance Standard for Children and Teenagers (CAAQAS). Neuropsychiatric Disease and Treatment [Internet]. 2024 Dec [cited 2024 Dec 10],Volume 20(1):2603–28. Available from: https://doi.org/10.2147/ndt.s472923
11. Post RE, Kurlansik SL. Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults. American Family Physician [Internet]. 2012 May 1 [cited 2024 Dec 10],85(9):890–6. Available from: https://www.aafp.org/pubs/afp/issues/2012/0501/p890.html
12. Young S, Hollingdale J, Absoud M, Bolton P, Branney P, Colley W, et al. Guidance for Identification and Treatment of Individuals with Attention deficit/hyperactivity Disorder and Autism Spectrum Disorder Based upon Expert Consensus. BMC Medicine [Internet]. 2020 May 25 [cited 2024 Dec 10],18(146). Available from: https://doi.org/10.1186/s12916-020-01585-y
13. Flynn McCarthy L. ADHD Medications for Children [Internet]. ADDitude. 2006 [cited 2024 Dec 10]. Available from: https://www.additudemag.com/adhd-medications-for-children/?srsltid=AfmBOorudC1y2U_g3RN-sJgIlSQJ9G9lWQyDE63DDZ1GQssMQpKMq-eg
14. CHADD. Psychosocial Treatment [Internet]. CHADD. 2022 [cited 2025 Dec 10]. Available from: https://chadd.org/for-professionals/psychosocial-treatment/
15. Capozzi L. Future Directions for Psychosocial Interventions for Children and Adolescents with ADHD [Internet]. Chop.edu. 2020 [cited 2024 Dec 10]. Available from: https://policylab.chop.edu/article/future-directions-psychosocial-interventions-children-and-adolescents-adhd
16. Minkoff NB. ADHD in Managed Care: An Assessment of the Burden of Illness and Proposed Initiatives to Improve Outcomes [Internet]. Ajmc.com. AJMC, 2009 [cited 2024 Dec 10]. Available from: https://www.ajmc.com/view/a219_09may_minkoff_s151to159
17. Herrera N, Cibrian FL, Silva LM, Beltran JA, Schuck SEB, Hayes GR, et al. Digital health intervention for children with ADHD to improve mental health intervention, patient experiences, and outcomes: a study protocol. BMC Digital Health [Internet]. 2024 Nov 5 [cited 2024 Dec 10],2(1). Available from: https://doi.org/10.1186/s44247-024-00134-4
18. Olatunji G, Faturoti O, Jaiyeoba B, Toluwabori AV, Adefusi T, Olaniyi P, et al. Navigating unique challenges and advancing equitable care for children with ADHD in Africa: a review. Annals of Medicine and Surgery (2012) [Internet]. 2023 Oct 1 [cited 2024 Dec 10],85(10):4939–46. Available from: https://pubmed.ncbi.nlm.nih.gov/37811061/